Drug · CHEMBL16
PHENYTOIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PHENYTOIN. Drugs and targets, record CHEMBL16. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL16
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Diphenylhydantoin, Epamin, Fenitoina, Lepitoin, NSC-8722, PHENYTOIN COMPONENT OF SM-88, Phenytoine, Phenytoinum, Zentropil
- ChEMBL
- Open Targets' highest stage
- Approval, for 2 of its 22 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets10
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SCN10A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6336 |
| SCN11A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/11280 |
| SCN1A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6323 |
| SCN2A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6326 |
| SCN3A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6328 |
| SCN4A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6329 |
| SCN5A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6331 |
| SCN7A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6332 |
| SCN8A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6334 |
| SCN9A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6335 |
Source ChEMBL
Diseases22
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 22Source Open Targets
See all 22 diseasesTrials72
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00510783 | IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures | Phase 4 | 158 | 2013-08-05 | phenytoin | Its name | ClinicalTrials.gov |
| NCT03512756 | A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer | Phase 2/3 | 130 | 2024-11-06 | phenytoin, sm-88 | Its name | ClinicalTrials.gov |
| NCT02939937 | Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis | Phase 2 | 71 | 2019-08-12 | phenytoin | Its name | ClinicalTrials.gov |
| NCT00618436 | Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention | Phase 4 | 52 | 2014-04-07 | phenytoin | Its name | ClinicalTrials.gov |
| NCT00774306 | Antiepileptic Drugs and Vascular Risk Markers | 52 | 2014-11-25 | phenytoin | Its name | ClinicalTrials.gov | |
| NCT02283827 | Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin. | Phase 1 | 32 | 2014-12-18 | phenytoin | Its name | ClinicalTrials.gov |
| NCT01355068 | A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From Australia | Phase 1 | 26 | 2011-12-14 | phenytoin | Its name | ClinicalTrials.gov |
| NCT02595723 | Phenytoin for Memory Impairment Secondary to Megestrol | Phase 4 | 21 | 2019-09-09 | phenytoin | Its name | ClinicalTrials.gov |
| NCT00581893 | Phenytoin and Driving Safety: A Randomized, Controlled Cross-Over Study | Phase 4 | 20 | 2021-07-01 | phenytoin | Its name | ClinicalTrials.gov |
| NCT00591006 | Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes | Phase 3 | 17 | 2015-08-19 | phenytoin | Its name | ClinicalTrials.gov |
1 to 10 of 72
See all 72 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Phenytoin/Fosphenytoin vs Levetiracetam: Number of Participants Who Experienced a Recurrent Seizure After Treatment. | 2 of 82 | 3 of 76 | 158 | NCT00510783 | Trial comparisons |
| Phenytoin/Fosphenytoin vs Levetiracetam: serious adverse events | 0 of 82 | 0 of 76 | 158 | NCT00510783 | Trial comparisons |
| Phenytoin vs Placebo: deaths from any cause | 0 of 21 | 0 of 50 | 71 | NCT02939937 | Trial comparisons |
| Phenytoin vs Placebo: serious adverse events | 1 of 21 | 0 of 50 | 71 | NCT02939937 | Trial comparisons |
| Levetiracetam vs Phenytoin: Seizure Incidence | 5 of 34 | 3 of 18 | 52 | NCT00618436 | Trial comparisons |
| Levetiracetam vs Phenytoin: serious adverse events | 0 of 34 | 0 of 18 | 52 | NCT00618436 | Trial comparisons |
| Epanutin Infatabs 50 mg vs Dilantin Infatabs 50 mg: serious adverse events | 0 of 24 | 0 of 26 | 50 | NCT01355068 | Trial comparisons |
| Phenytoin vs Placebo: Number of Subjects Who Had a Driving Simulator Crash Event | 2 of 20 | 0 of 20 | 40 | NCT00581893 | Trial comparisons |
| Phenytoin vs Placebo: deaths from any cause | 0 of 20 | 0 of 20 | 40 | NCT00581893 | Trial comparisons |
| Phenytoin vs Placebo: serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT00581893 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials14
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 23864647 | RESULT | 1 | PubMed |
| 42751727 | DERIVED | 1 | PubMed |
| 40997284 | DERIVED | 1 | PubMed |
| 36273216 | DERIVED | 1 | PubMed |
| 35866376 | DERIVED | 1 | PubMed |
| 35499204 | DERIVED | 1 | PubMed |
| 34930487 | DERIVED | 1 | PubMed |
| 32924093 | DERIVED | 1 | PubMed |
| 31156538 | DERIVED | 1 | PubMed |
| 27878474 | DERIVED | 1 | PubMed |
1 to 10 of 14
See all 14 papers from its trialsTests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Verbal Learning | 2 | 2 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL16
GET https://conductscience.org/api/drugs/v1/CHEMBL16/diseases?page=2